fluorogenic substrate mca-pro-leu-gly-leu-dpa-ala-arg-nh 2 ·tfa (Merck KGaA)
Structured Review
Fluorogenic Substrate Mca Pro Leu Gly Leu Dpa Ala Arg Nh 2 ·Tfa, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+fluorogenic+substrate/fluorogenic+substrate+mca+pro+leu+gly+leu+dpa+ala+arg+nh+2+%C2%B7tfa/pmc11416218-403-29-46
Average 90 stars, based on 1 article reviews
Images
Related Articles
Activity Assay:Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA). Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats. Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14. Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM Purification:Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA). Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats. Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14. Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM Concentration Assay:Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA). Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats. Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14. Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM Inhibition:Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA). Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats. Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14. Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM Fluorescence:Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA). Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats. Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy Article Snippet: The inhibition of the catalytic activity of Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14. Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM |
